A Phase 3 interventional study of insulin degludec and placebo in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 132 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-25.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 37th largest by enrollment, is one of 6 that started in 2012, is one of 49 in phase 3, and was the 29th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 6 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 346 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 153rd largest by enrollment of the 428 interventional ones that give a count, is one of 24 that started in 2012, is one of 187 in phase 3, and was the 316th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Africa, Asia, Europe and North America. The purpose of the trial is to investigate the effect of insulin degludec (IDeg) in combination with liraglutide (Lira) and metformin (at least 1500 mg daily or maximum tolerated dose) in subjects with type 2 diabetes qualifying for treatment intensification.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 346 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec · Drug: liraglutide
Drug: placebo · Drug: liraglutide
Administered s.c. (under the skin) once daily. Dose individually adjusted.
Administered s.c. (under the skin) once daily. Dose individually adjusted.
Administered s.c. (under the skin) once daily. Dose: 1.8 mg.
Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%)
Change from baseline in HbA1c after 26 weeks of treatment
Time frame: Week 0, week 26
Change From Baseline in Fasting Plasma Glucose (FPG)
Change from baseline in FPG after 26 weeks of treatment
Time frame: Week 0, week 26
Number of Responders for HbA1c (Below 7.0 %)
Number of responders for HbA1c below 7.0%, after 26 weeks of randomised treatment.
Time frame: After 26 weeks of randomised treatment.
Change From Baseline in Mean Pre-breakfast Measurements Used for Titration
Change from baseline after 26 weeks of treatment in the average of the pre-breakfast self measured plasma glucose (SMPG) measured on the day of the contact and the two days immediately prior to the contact. The least squares means presented are the estimated values after 26 weeks of treatment and the statistical analysis presents the treatment difference of the change from baseline values as the model is adjusted for baseline.
Time frame: Week 0, week 26
Change From Baseline in 8-point Profile
The change from baseline in the 8-point SMPG profile after 26 weeks of randomised treatment. The least squares means presented are the estimated values after 26 weeks of treatment and the statistical analysis presents the treatment difference of the change from baseline values as the model is adjusted for baseline.
Time frame: Week 0, week 26
Change From Baseline in Mean of the 8-point Profile
Change from baseline in mean of the 8-point profile after 26 weeks of randomised treatment.
Time frame: Week 0, week 26
Number of Hypoglycaemic Episodes
Number of confirmed hypoglycaemic episodes from week 0 to 26 weeks of randomised treatment. A hypoglycaemic episode was defined as treatment emergent if the onset of the episode occurred after the first administration of investigational medicinal product and no later than 7 days after the last day on trial product. Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia or minor hypoglycaemic episodes.
Time frame: Weeks 0 - 26
Number of Adverse Events
Number of treatment emergent AEs (TEAEs) from week 0 to week 26 of the randomised treatment. A TEAE was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.
Time frame: Weeks 0 - 26
Change From Baseline in Patient Reported Health-related Quality of Life Using the Short-Form 36 Health Survey Version 2 (SF-36®v2)
Change in subject's quality of life was evaluated using the Short-Form 36 Health Survey version 2 (SF-36®v2). Evaluations were performed at baseline and at the last treatment visit (week 26). SF-36 was assessed on a scale range of 0.65 to 80.73 for physical health and -8.81 to 81.65 for mental health respectively, where higher scores indicated a better quality of life. 0-100 scores from the SF-36 were converted to a norm-based score using a T-score transformation in order to obtain a direct interpretation in relation to the distribution of the scores in the 1998 U.S. general population.
Time frame: Week 0, week 26
The trial was conducted at 129 sites in 11 countries randomised subjects: Canada (7), France (10), Germany (8), Israel (6), Italy (7), Serbia (7), South Africa (6), Ukraine (4), United Arab Emirates (3), United Kingdom (6), and United States (65).
| Milestone | IDeg | Placebo |
|---|---|---|
| Started | 174 | 172 |
| Exposed | 173 | 170 |
| Completed | 160 | 131 |
| Not completed | 14 | 41 |
| Withdrew: Adverse event | 5 | 3 |
| Withdrew: Protocol violation | 3 | 5 |
| Withdrew: Withdrawal criteria | 1 | 4 |
| Withdrew: Unclassified | 5 | 29 |
Change from baseline in HbA1c after 26 weeks of treatment
| percentage of glycosylated haemoglobin | IDeg | Placebo |
|---|---|---|
| Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) | -0.99 ± 0.08 | -0.07 ± 0.08 |
Change from baseline in FPG after 26 weeks of treatment
| mmol/L | IDeg | Placebo |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) | -2.60 ± 2.91 | -0.28 ± 2.44 |
Number of responders for HbA1c below 7.0%, after 26 weeks of randomised treatment.
| percentage (%) of subjects | IDeg | Placebo |
|---|---|---|
| Number of Responders for HbA1c (Below 7.0 %) | 77.6 | 35.5 |
Change from baseline after 26 weeks of treatment in the average of the pre-breakfast self measured plasma glucose (SMPG) measured on the day of the contact and the two days immediately prior to the contact. The least squares means presented are the estimated values after 26 weeks of treatment and the statistical analysis presents the treatment difference of the change from baseline values as the model is adjusted for baseline.
| mmol/L | IDeg | Placebo |
|---|---|---|
| Change From Baseline in Mean Pre-breakfast Measurements Used for Titration | 5.88 ± 0.14 | 8.23 ± 0.15 |
The change from baseline in the 8-point SMPG profile after 26 weeks of randomised treatment. The least squares means presented are the estimated values after 26 weeks of treatment and the statistical analysis presents the treatment difference of the change from baseline values as the model is adjusted for baseline.
| mmol/L | IDeg | Placebo |
|---|---|---|
| Before breakfast, N=170, 164 | 5.85 ± 0.15 | 8.54 ± 0.16 |
| 90 min after breakfast, N=153, 148 | 7.65 ± 0.24 | 9.75 ± 0.25 |
| Before lunch, N=151,149 | 6.33 ± 0.18 | 8.34 ± 0.19 |
| 90 min after lunch, N=152,150 | 7.73 ± 0.21 | 9.67 ± 0.21 |
| Before evening meal, N=154,148 | 6.77 ± 0.20 | 9.51 ± 0.21 |
| 90 mins after evening meal, N=147,145 | 7.93 ± 0.21 | 9.65 ± 0.22 |
| Before bedtime, N=148, 142 | 7.21 ± 0.20 | 8.95 ± 0.21 |
| Before breakfast the next day, N=164,161 | 6.05 ± 0.17 | 8.55 ± 0.18 |
Change from baseline in mean of the 8-point profile after 26 weeks of randomised treatment.
| mmol/L | IDeg | Placebo |
|---|---|---|
| Change From Baseline in Mean of the 8-point Profile | -2.3 ± 1.8 | -0.5 ± 1.7 |
Number of confirmed hypoglycaemic episodes from week 0 to 26 weeks of randomised treatment. A hypoglycaemic episode was defined as treatment emergent if the onset of the episode occurred after the first administration of investigational medicinal product and no later than 7 days after the last day on trial product. Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia or minor hypoglycaemic episodes.
| events | IDeg | Placebo |
|---|---|---|
| Number of Hypoglycaemic Episodes | 47 | 9 |
Number of treatment emergent AEs (TEAEs) from week 0 to week 26 of the randomised treatment. A TEAE was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.
| events | IDeg | Placebo |
|---|---|---|
| Number of Adverse Events | 285 | 252 |
Change in subject's quality of life was evaluated using the Short-Form 36 Health Survey version 2 (SF-36®v2). Evaluations were performed at baseline and at the last treatment visit (week 26). SF-36 was assessed on a scale range of 0.65 to 80.73 for physical health and -8.81 to 81.65 for mental health respectively, where higher scores indicated a better quality of life. 0-100 scores from the SF-36 were converted to a norm-based score using a T-score transformation in order to obtain a direct interpretation in relation to the distribution of the scores in the 1998 U.S. general population.
| T-scores | IDeg | Placebo |
|---|---|---|
| Physical health | 0.5 ± 6.3 | 0.0 ± 6.2 |
| Mental health | 0.6 ± 8.1 | -0.7 ± 8.8 |
Collected over The adverse events were collected in a time frame of 26 weeks + 7 days follow up. Adverse event with an onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IDeg | — | 6/173 (3.5%) | 33/173 (19.1%) |
| Placebo | — | 9/170 (5.3%) | 32/170 (18.8%) |
| Event | IDeg | Placebo |
|---|---|---|
| Atrial fibrillationCardiac disorders | 0/173 | 1/170 |
| Cardiac failureCardiac disorders | 0/173 | 1/170 |
| Cardiac failure congestiveCardiac disorders | 0/173 | 1/170 |
| TachycardiaCardiac disorders | 0/173 | 1/170 |
| Ventricular tachycardiaCardiac disorders | 0/173 | 1/170 |
| Upper respiratory tract infectionInfections and infestations | 0/173 | 1/170 |
| UrosepsisInfections and infestations | 0/173 | 1/170 |
| Humerus fractureInjury, poisoning and procedural complications | 0/173 | 1/170 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/173 | 1/170 |
| Transitional cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/173 | 1/170 |
| Event | IDeg | Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 14/173 | 11/170 |
| DiarrhoeaGastrointestinal disorders | 10/173 | 13/170 |
| Lipase increasedInvestigations | 10/173 | 13/170 |
| Age, Continuous(years) | IDeg | Placebo | Total |
|---|---|---|---|
| Mean | 57.0 ± 10.0 | 57.3 ± 9.4 | 57.2 ± 9.7 |
| Sex: Female, Male(Participants) | IDeg | Placebo | Total |
|---|---|---|---|
| Female | 76 | 68 | 144 |
| Male | 98 | 104 | 202 |
| Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin) | IDeg | Placebo | Total |
|---|---|---|---|
| Mean | 7.5 ± 0.6 | 7.6 ± 0.6 | 7.6 ± 0.6 |
| Fasting plasma glucose (FPG)(mmol/L) | IDeg | Placebo | Total |
|---|---|---|---|
| Mean | 8.7 ± 2.1 | 9.1 ± 2.2 | 8.9 ± 2.2 |
Showing the first 100 of 132 sites across 11 countries. Choose a country and city above to see the rest.
Ran from Oct 2012 to primary completion in Dec 2013, 14 months.
Results were first posted in Apr 2016, 2 years 3 months after primary completion. A results delay was requested in Jan 2014.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 14 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin degludec